The FDA has approved the first pill, called Zurzuvae, to treat severe postpartum depression in new mothers. Developed by Sage Therapeutics, the pill offers an oral treatment option that has shown strong effects in reducing depression symptoms over a four- to six-week period in studies. Zurzuvae works differently from traditional antidepressants, targeting a distinct brain pathway. While experts acknowledge its potential, some call for more extended follow-up data beyond the initial 45 days. The pill’s milder side effects and faster onset of benefits make it a notable alternative to existing treatments. Pricing details and its impact on prescription rates remain to be seen.
Source : CGTN